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Summary
Background More than 1·5 billion people are aﬀ ected by schistosomiasis or soil-transmitted helminthiasis. WHO’s 
recommendations for mass drug administration (MDA) against these parasitic infections emphasise treatment of 
school-aged children, using separate treatment guidelines for these two helminthiases groups. We aimed to evaluate 
the cost-eﬀ ectiveness of expanding integrated MDA to the entire community in four settings in Côte d’Ivoire.
Methods We extended previously published, dynamic, age-structured models of helminthiases transmission to 
simulate costs and disability averted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and 
soil-transmitted helminthiasis. We calibrated the model to data for prevalence and intensity of species-speciﬁ c 
helminth infection from surveys undertaken in four communities in Côte d’Ivoire between March, 1997, 
and September, 2010. We simulated a 15-year treatment programme with 75% coverage in only school-aged children; 
school-aged children and preschool-aged children; adults; and the entire community. Treatment costs were estimated 
at US$0·74 for school-aged children and $1·74 for preschool-aged children and adults. The incremental cost-
eﬀ ectiveness ratio (ICER) was calculated in 2014 US dollars per disability-adjusted life-year (DALY) averted.
Findings Expanded community-wide treatment was highly cost eﬀ ective compared with treatment of only school-aged 
children (ICER $167 per DALY averted) and WHO guidelines (ICER $127 per DALY averted), and remained highly 
cost eﬀ ective even if treatment costs for preschool-aged children and adults were ten times greater than those for 
school-aged children. Community-wide treatment remained highly cost eﬀ ective even when elimination of helminth 
infections was not achieved. These ﬁ ndings were robust across the four diverse communities in Côte d’Ivoire, only 
one of which would have received annual MDA for both schistosomiasis and soil-transmitted helminthiasis under 
the latest WHO guidelines. Treatment every 6 months was also highly cost eﬀ ective in three out of four communities.
Interpretation Integrated, community-wide MDA programmes for schistosomiasis and soil-transmitted helminthiasis 
can be highly cost eﬀ ective, even in communities with low disease burden in any helminth group. These results 
support an urgent need to re-evaluate current global guidelines for helminthiases control programmes to include 
community-wide treatment, increased treatment frequency, and consideration for lowered prevalence thresholds for 
integrated treatment.
Funding Stanford University Medical Scholars Programme, Mount Sinai Hospital-University Health Network AMO 
Innovation Fund.
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Introduction
Elimination of schistosomiasis and soil-transmitted 
helminthiasis poses a great challenge, but is an even 
greater opportunity to alleviate the suﬀ ering of the more 
than 1·5 billion people who are infected with the parasitic 
worms that give rise to these diseases.1,2 Discussions 
surrounding helminth infections, a subset of the neglected 
tropical diseases, have shifted from control to elimination 
in the past few years.3,4 This change has been shown in the 
increased international funding for mass treatment 
campaigns from foreign aid programmes, non-
governmental organisations, and philanthropy, in addition 
to expanded drug donation programmes by 
pharmaceutical companies.3,5 To achieve these ambitious 
aims, WHO issued a roadmap3 for the control and 
elimination of neglected tropical diseases, which advocates 
for expansion of mass drug administration (MDA) to 
address the large disease burden of helminthiases, 
including schistosomiasis and soil-transmitted 
helminthiasis (caused by infection with Ascaris 
lumbricoides, the two hookworm species Ancylostoma 
duodenale and Necator americanus, and Trichuris trichiura).
Consistent with published guidelines by WHO,6 MDA 
programmes provide large-scale empirical drug 
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distribution irrespective of individual infection status 
and have previously targeted school-aged children (aged 
5–14 years) through school-based delivery schemes 
(appendix). This approach has been universally viewed as 
cost eﬀ ective and practical, since children are believed to 
harbour a higher disease burden and greater disability 
than adults do. Additionally, schools provide an eﬀ ective 
distribution platform and drugs are often donated by 
pharmaceutical companies for these purposes.6–8 
However, despite the eﬀ orts of regular MDA campaigns, 
the disease burden of schistosomiasis and soil-
transmitted helminthiasis has remained high.9,10 The 
latest WHO recommendations6,11 are used to guide MDA 
strategies, but were developed without a goal of 
elimination, are not based on a cost-eﬀ ectiveness 
framework, and provide separate treatment 
recommendations for schistosomiasis and soil-
transmitted helminthiasis with little guidance for the 
role of integrated treatment programmes. Recent work in 
the past two years has suggested the importance of 
expansion of MDA to additional age groups to overcome 
high reinfection rates and potentially enable elimination 
of these diseases.5,12,13 However, the cost-eﬀ ectiveness of 
expanding treatment to additional age groups is 
unknown.
Crucial, policy-relevant questions remain about the 
cost-eﬀ ectiveness of integrated MDA programmes that 
might vary substantially in diﬀ erent contexts and 
settings—eg, when treatment is provided to the entire 
community (rather than school-aged children only), 
whether elimination of diseases is met or not, 
administration of diﬀ erent frequencies and treatment 
coverage, and the varying prevalence and intensities of 
infection in communities. To address these policy-
relevant scenarios, we modelled the cost-eﬀ ectiveness of 
MDA strategies for schistosomiasis and soil-transmitted 
helminthiasis using data from four communities in 
Côte d’Ivoire and compared integrated, community-wide 
MDA with treatment of only school-aged children, 
current WHO guidelines, and other MDA scenarios.6
Methods
Model overview
We extended the work of existing transmission models 
for helminth infections13–15 to include multiple helminth 
infections, disability estimates, costs, and simulation of 
integrated treatment targeted with praziquantel for 
schistosomiasis and albendazole for soil-transmitted 
helminthiasis. By use of empirical data from four 
communities in Côte d’Ivoire, we simulated communities 
of 5000 people and projected age-speciﬁ c prevalence and 
intensity of infections (ie, mean worm burden, often 
measured in eggs per g of faeces) over 15 years.16–20
We compared annual MDA for school-aged children 
alone; school-aged children and preschool-aged children 
(aged 2–4 years); adults alone (aged ≥15 years); and the 
entire community, using no treatment as a base case. 
Each treatment strategy was applied for 15 years. 
Strategies were compared with treatment intervals of 
3 months, 4 months, 6 months, 1 year, 2 years, 3 years, 
and 4 years.6 We modelled the total disability averted and 
direct costs of MDA treatment programmes in four 
simulated communities of 5000 people in Côte d’Ivoire 
(A–D) to model medium-sized communities.
We deﬁ ned direct costs in 2014 US dollars (US$) and 
measured total disability averted in the disability-adjusted 
life-year (DALY) after published sequelae and weights.1,8,21–23 
Cost-eﬀ ectiveness was measured with the incremental 
cost-eﬀ ectiveness ratio (ICER), deﬁ ned as the incremental 
cost divided by the incremental disability averted ($ per 
DALY averted). We deemed treatment strategies to be 
highly cost eﬀ ective if the ICER was below the per-capita 
Research in context 
Evidence before this study 
We searched PubMed for relevant articles published in English 
before Aug 22, 2015, using the search terms “helminth” or 
“schistosomiasis” together with “cost-eﬀ ectiveness” and 
“treatment” restricted to the title and abstract ﬁ elds. This search 
identiﬁ ed 34 articles. Of these, ten studies reported about the 
cost-eﬀ ectiveness of mass drug administration (MDA) against 
schistosomiasis or soil-transmitted helminthiasis alone and 
three studies discussed integrated treatment of schistosomiasis, 
soil-transmitted helminthiasis, or other diseases. However, none 
of these studies evaluated the cost-eﬀ ectiveness of integrated 
community-wide MDA against schistosomiasis and soil-
transmitted helminthiasis using the disability-adjusted life-year.
Added value of this study
Our ﬁ ndings suggest that integrated community-wide MDA 
with high coverage (>75%) and sustained administration 
(>5 years) against schistosomiasis and soil-transmitted 
helminthiasis could be crucial in decreasing community disease 
burden and lowering reinfection. Expanded community-wide 
MDA was highly cost eﬀ ective in four Côte d’Ivoire communities 
across a range of conditions, including when elimination could 
not be achieved. Increasing treatment intervals to every 
6 months was also reported to be highly cost eﬀ ective. This 
study goes beyond previous work to provide a rigorous 
multisetting cost-eﬀ ectiveness analysis to optimise MDA 
against two major groups of helminthiases.
Implications of all evidence available
Recent models and our ﬁ ndings support the need to revise 
global guidelines to address expansion of MDA to the 
entire community where these diseases are endemic, and 
improve guidance for integration of treatment programmes for 
schistosomiasis and soil-transmitted helminthiasis. Alternative 
or complementary interventions might also be needed to 
achieve elimination of these infections.
See Online for appendix
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gross domestic product of Côte d’Ivoire ($1521 in 2013).24 
Future costs and disability averted were discounted at 
3% per year, and undiscounted results are also presented.25
Transmission model and assumptions
We adapted a dynamic, age-structured, and deterministic 
transmission model to project population-level burden of 
helminth infections during the 15-year simulation 
period. We simultaneously modelled the transmission 
dynamics of ﬁ ve helminths: Schistosoma haematobium, 
Schistosoma mansoni, A lumbricoides, T trichiura, and 
hookworm. Every helminth type’s lifecycle was modelled 
by tracking the mean worm burden in every age group. 
This process is driven by the production of eggs and 
excretion of this infectious material into the environment, 
uptake of infectious material through either ingestion of 
eggs or contact with larvae, and mortality of the worm 
within the host (appendix). Individuals were modelled as 
susceptible to reinfection immediately after treatment. 
On the basis of previous models and empirical 
observation of helminthiases distribution, prevalence of 
helminth infection was assumed to follow a negative 
binomial distribution with respect to burden of infection 
(worm burden or eggs per g [S haematobium is measured 
in eggs per 10 mL urine]).12–15 This distribution was 
recalculated at every time step of the model (1 month). A 
heterogeneous mixing model was derived to allow 
various extents of interaction between age groups and 
the environment. Reproduction number and exposure 
rate were calculated from primary epidemiological data 
speciﬁ c to each Côte d’Ivoire community and age group, 
using the assumption that preschool-aged children and 
school-aged children contributed twice the relative 
amount of eggs to the environment than did adults 
(appendix).13
Treatment and disability model and assumptions
We modelled the treatment eﬀ ect of MDA with 
praziquantel (for schistosomiasis) and albendazole (for 
soil-transmitted helminthiasis) on prevalence of 
helminth infections and DALYs. Treatment was modelled 
Infection 
intensity*
Disability 
weights 
Schistosoma mansoni
Infection21 All 0·005–0·02
Schistosoma haematobium
Infection21 All 0·005–0·02
Ascaris lumbricoides
Mild abdominopelvic problems Moderate 0·0108
Symptomatic infection Heavy 0·0296
Wasting† Heavy 0·1245
Trichuris trichiura
Mild abdominopelvic problems Moderate 0·0108
Symptomatic infection Heavy 0·0296
Wasting† Heavy 0·1245
Hookworm
Mild abdominopelvic problems Moderate to heavy 0·0108
Wasting† Heavy 0·1245
Anaemia
Mild anaemia‡ All 0·0041
Moderate anaemia‡ All 0·0056
Severe anaemia‡ All 0·1615
All infection intensities include light, moderate, and heavy infections. Table 
adapted from Pullan and colleagues,1 with permission. *Based on eggs per g in 
faeces (appendix). †Wasting was applied to only a subset of children harbouring a 
heavy infection. ‡Anaemia averted through treatment was calculated 
independent of intensity of infection, and modelled separately as a result of 
either hookworm infection or schistosomiasis.
Table 1: Disability weights for infections with Schistosoma and soil-
transmitted helminths
Base-case value
Baseline cohort characteristics
Mean age (SD), years16–20 27·3 (19·6)
Age groups38
Preschool children 10%
School-aged children 25%
Adults 65%
Women 50%
Community population, n 5000
Mean Hb (SD), g/L33
Men 134 (19)
Women 111 (16)
Children 112 (15)
National child wasting34 7·0%
Cost (2014 US$) and treatment parameters per person
Drugs
Albendazole, 400 mg6,7,39 $0·03 
Praziquantel, 40 mg/kg6–8,39 $0·21 
Method of delivery
School-based delivery6–8,40–48 $0·50 
Community-based delivery*8,45,48 $1·50 
Drugs plus school-based delivery $0·74
Drugs plus community-based delivery $1·74
Treatment coverage in all communities3 75%
Praziquantel and albendazole EPG reduction27–29
Schistosoma spp 85%
Hookworm 89·5%
Ascaris lumbricoides 97·5%
Trichuris trichiura 64%
Life expectancy (years)15
Schistosoma spp 4
Hookworm 2·5
A lumbricoides 1·5
T trichiura 1·5
Hb=haemoglobin. EPG=eggs per g of faeces (except for Schistosoma haematobium 
that is measured in eggs per 10 mL of urine). *Community-based delivery was 
assumed to be three times the cost of school-based delivery. 
Table 2: Baseline cohort characteristics and selected cost, treatment, 
and epidemiological parameters
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as an instant reduction in mean worm burden,5,8,12–14,26 
estimated from extent of reduction of eggs per g of faeces 
reported in clinical trials.27–29 We used a treatment 
coverage of 75% to adhere with the WHO goal for 
helminthiases MDA by 2020.3
Disability was calculated on the basis of the infection 
intensity of individuals within the population and 
updated disability weights (DALYs; table 1).1,8,21–23 For soil-
transmitted helminthiasis, the population was divided 
into four categories—no infection, light intensity, 
moderate intensity, and heavy intensity infection—with 
associated sequelae based on eggs per g of faeces, which 
was used as an indicator for severity of infection. 
Schistosomiasis was treated as binary, whereby 
individuals were either regarded as uninfected or infected 
according to reported disability weights.21,23
Anaemia was modelled by a calculation of the 
proportion of mild, moderate, and severe anaemia that 
resolved through treatment of hookworm infection and 
schistosomiasis. This calculation consisted of a mixture 
model methodology and documented downward shifts in 
haemoglobin for any individual with hookworm infection 
or schistosomiasis (appendix).30–33 Wasting was estimated 
by determining the proportion of national child wasting 
in Côte d’Ivoire attributable to heavy helminth infections 
on the basis of reported Z-score estimates of the 
reduction in weight for height due to heavy helminth 
infection.34,35
Polyparasitism is common in Côte d’Ivoire36 and was 
modelled under the assumptions that acquisition of each 
infection was independent from one another, which was 
supported by an absence of strong or consistent 
correlation between infections detected from cross-
sectional surveys completed in Côte d’Ivoire (appendix). 
Disability for individuals with polyparasitism and 
multiple sequelae were treated as multiplicative following 
convention.37
Input epidemiological and cost data
For epidemiological parameters speciﬁ c to every 
community and age group, we used primary age-
structured data on prevalence and intensity of infection 
of Schistosoma and soil-transmitted helminths from 
cross-sectional surveys done in four separate untreated 
communities with diverse geography and climate within 
Côte d’Ivoire.16–20 Prevalence and intensity of infection 
were adjusted for imperfect diagnostics (appendix).
Treatment costs included both drug and delivery costs, 
and were calculated from the perspective of ﬁ nancial 
costs of a neglected tropical diseases treatment 
programme under the framework of a national campaign 
(table 2). School-based delivery costs were applied to 
school-aged children, and community-based delivery 
costs were used for preschool-aged children and adults. 
These costs were estimated from the scientiﬁ c literature 
and the International Drug Price Indicator Guide, and 
reﬂ ected the cost of praziquantel, albendazole, and 
delivery costs, adjusted through the US Consumer Price 
Index to 2014 US dollars. We conservatively assumed 
that praziquantel and albendazole were not donated, and 
priced at $0·21 and $0·03, respectively.6–8,39 School-based 
delivery costs were estimated at $0·50, which represent 
the higher end of price estimations from the 
literature.7,8,40–48 Estimated delivery costs from the 
literature included drug shipment, vehicle use, staﬀ 
salaries, planning costs, technical support, and daily 
compensation, among other included costs. Indirect 
delivery costs associated with volunteer time for school-
based delivery (eg, teachers) were not explicitly included 
in many of these estimations. Community treatment 
was assumed to have delivery costs that were three times 
Figure 1: Baseline epidemiology of four communities in Côte d’Ivoire and associated WHO-recommended 
control programmes
(A) Initial observed helminth prevalence and (B) WHO guidelines6,11 for helminthiases control programmes with 
associated prevalence values that categorise the risk for schistosomiasis and soil-transmitted helminthiasis of 
communities A–D.16–20 STH=soil-transmitted helminthiasis. Pre-SAC=preschool-aged children. SAC=school-
aged children.
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that of school-based programmes because of the 
increased logistical costs of community delivery and 
remuneration to community health workers.8,45,48 
Although we did not scale delivery costs with the size of 
the treated population, we used cost estimations that 
were conservative and did not assume advantages from 
economies of scale. The composite cost for treatment 
was estimated to be $0·74 for school-aged children and 
$1·74 for community treatment to preschool-aged 
children and adults.7,8,29
Statistical analysis
We did a series of one-way sensitivity analyses and a 
probabilistic sensitivity analysis by varying key 
parameters of our model across a range of feasible 
values. We used these data to determine the robustness 
of our results and the eﬀ ect of speciﬁ c assumptions. Our 
one-way sensitivity analyses assessed the eﬀ ect of varying 
one parameter on the ICER value of integrated 
community-wide treatment compared with targeting 
only school-aged children. We examined the most 
inﬂ uential parameters, including the school-based and 
community-based delivery cost, disability weight for 
schistosomiasis, frequency of treatment, coverage, and 
association between the relative contribution of infectious 
material into the environment between preschool-aged 
children, school-aged children, and adults (appendix). 
The authors fully support the importance of data sharing 
and transparency in research; full model code and data 
are available on request to the authors.
Role of the funding source
The funder of this study had no role in the design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Four communities in Côte d’Ivoire were surveyed 
between March, 1997, and September, 2010, for helminth 
infections.16–20 The prevalence of helminth infections 
investigated was highly variable between age groups and 
the four communities (ﬁ gure 1A, appendix). All four 
communities had a higher prevalence of helminth 
infections in adults than in school-aged children. Of the 
four communities, communities A and B had high 
burdens (>50% prevalence in school-aged children) for 
schistosomiasis, whereas communities C and D had a 
moderate burden (10–50%). Communities B, C, and D 
had a low burden (20–50% prevalence among school-
aged children) for soil-transmitted helminthiasis, 
whereas community A was deemed no risk (<20%). 
Following WHO guidelines for helminthiases control 
programmes, the four communities would have been 
classiﬁ ed under three unique recommendations for 
MDA (ﬁ gure 1B).
Figure 2: Eﬀ ect of expanding treatment to broader age groups and increasing coverage on combined 
helminth burden and mean prevalence
A heterogeneous population of preschool-aged children (pre-SAC), school-aged children (SAC), and adults in 
Côte d’Ivoire who received annual treatment; SAC only with 75% coverage (A and B), annual community-wide 
treatment with 25% coverage (C and D), and annual community-wide treatment with 75% coverage (E and F) 
which approached elimination. Reproduction number and beta ratios were ﬁ tted to initial epidemiological data 
from Côte d’Ivoire. Mean prevalence represents the independent combination of all ﬁ ve helminth species. Pre-SAC 
and SAC were assumed to have twice the reproduction number of adults. EPG=eggs per g of faeces.
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SAC only $34 122 $41 625 2964·1 3718·6 118
SAC and pre-SAC $66 214 $80 775 2899·9 3636·3 Dominated*
Adults only $208 603 $254 475 2429·3 3033·4 Dominated*
Community-wide $274 817 $335 250 1521·6 1836·5 167
Costs and disability are discounted at 3% annually. DALY=disability-adjusted life-year. ICER=incremental cost-
eﬀ ectiveness ratio. NA=not applicable. SAC=school-aged children (5–14 years). Pre-SAC=preschool-aged children 
(2–4 years). *Dominated strategy deﬁ ned as intervention with higher ICER than more eﬀ ective strategy.
Table 3: Costs, disability, and incremental cost-eﬀ ectiveness of strategies for integrated mass drug 
administration to treat schistosomiasis and soil-transmitted helminthiasis in Côte d’Ivoire
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In the four simulated communities of 5000 people in 
Côte d’Ivoire (A–D), the total disability attributable 
to helminth infections, in the absence of treatment, 
was projected to be 3252·1 DALYs (undiscounted 
4090·7 DALYs) during 15 years (table 3). Schistosomiasis 
was the leading cause of disability in all four communities. 
Most disability resulted from Schistosoma infections (92%) 
and combined anaemia from hookworm and 
schistosomiasis (6%; appendix). Notably, T trichiura and 
A lumbricoides infections together accounted for only 
1% of total disability.
We modelled the eﬀ ect of changing coverage of 
treatment and inclusion of broader age groups (preschool-
aged children and adults) on mean burden and prevalence. 
For most helminth species and communities, approaching 
elimination required substantial treatment coverage 
(>75% of the population), sustained administration 
(>5 years), and broad inclusion of age groups (community-
wide treatment). By comparison, the latest WHO 
guidelines6,11 that propose annual treatment of only school-
aged children with 75% coverage resulted in a minimum 
decrease in prevalence and mean burden of helminths 
(ﬁ gure 2). Notably, the school-aged children and adult 
populations in community B who had high-intensity 
schistosomiasis and the preschool-aged children in 
community C with high-intensity T trichiura needed 
treatment every 6 months to approach elimination of 
these infections (data shown in appendix).
Implementation of an integrated MDA programme with 
75% coverage in school-aged children was a highly cost-
eﬀ ective intervention compared with giving no treatment. 
We projected that treatment of only school-aged children 
would avert 288 DALYs over 15 years at a cost of $34 122 
(ICER $118 per DALY averted [table 3], varying among the 
communities from $87 to $141 per DALY averted). Our 
model suggests that coverage of the entire community 
would result in an additional 1443 DALYs averted at an 
incremental cost of $240 695 (ICER $167 per DALY averted, 
varying among the communities from $101 to $463 per 
DALY averted). Community-wide MDA was therefore 
highly cost eﬀ ective by comparison with treatment of only 
school-aged children (table 3; appendix). Treatment of 
preschool-aged children and school-aged children together 
or adults alone was dominated by community-wide 
treatment, in that these alternative strategies had a higher 
ICER and lower overall eﬀ ectiveness than community-
wide treatment (appendix).
We also did a cost-eﬀ ectiveness analysis independently 
for all of the four communities (appendix). These 
communities ranged from low to high disease-burden 
regions, and varied in Schistosoma prevalence from 11% 
to 63%. In all settings, community-wide treatment was 
highly cost eﬀ ective compared with treatment of school-
aged children alone (appendix).
The cost-eﬀ ectiveness of all treatment strategies was 
quite robust across the full range of treatment coverage 
($149–277 per DALY averted from 100% to 5% coverage), 
suggesting that both control and elimination strategies 
were highly cost eﬀ ective (ﬁ gure 3). For three (A–C) of the 
four communities, community-wide administration 
showed improving cost-eﬀ ectiveness as the coverage rate 
increased above 50%. This occurrence was only reported 
in the community-wide treatment strategy, and was 
presumably a result of approaching elimination through 
broad inclusion of age groups and high coverage. More 
frequent treatments resulted in higher incremental cost-
eﬀ ectiveness of all strategies due to decreasing incremental 
gains (table 4). Nevertheless, more frequent treatment was 
highly cost eﬀ ective, including biannual treatment of 
school-aged children (ICER $347 per DALY averted) and 
community-wide treatment (ICER $335 per DALY averted) 
compared with annual treatment (see appendix for 
community analysis).
The proposed strategy of integrated community-wide 
treatment was highly cost eﬀ ective compared with 
Figure 3: Eﬀ ect of treatment coverage on cost-eﬀ ectiveness of mass drug administration against 
schistosomiasis and soil-transmitted helminthiasis in Côte d’Ivoire
The incremental cost-eﬀ ectiveness ratio (ICER) of community-wide treatment compared with treatment of 
school-aged children (SAC) alone was assessed across all coverage rates for communities A–D (A–D), and 
aggregated (E). The vertical line at 75% coverage was the base-case assumption in the analysis, and represents 
WHO’s 2020 goal for global coverage.3 DALY=disability-adjusted life-year.
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treatment following WHO guidelines (ie, treatment of 
school-aged children for schistosomiasis and soil-
transmitted helminthiasis, with additional treatment of 
preschool-aged children and women of childbearing age 
for soil-transmitted helminthiasis alone) with an ICER of 
$127 per DALY averted (appendix). Community-based 
treatment averted an additional 1364 DALYs compared 
with WHO guidelines during the 15-year simulation.
A series of one-way sensitivity analyses showed that 
expansion of treatment from school-aged children to 
community-wide treatment with 75% coverage would be 
highly cost eﬀ ective across a range of tested parameters 
(ﬁ gure 4). The base delivery cost and community delivery 
cost multiplier were the most important parameters, and 
were assessed by use of an upper end of $1·50 delivery 
cost per school-aged child and using a community delivery 
multiplier of up to ten times the cost of school-based 
delivery. The ICER was highly robust when varying the 
schistosomiasis disability weight, treatment frequency, 
coverage, and relative environmental contribution 
between preschool-aged children, school-aged children, 
and adults. The probabilistic sensitivity analysis, which 
varied many uncertain parameters simultaneously, was 
also used to assess the eﬀ ect of uncertainty in the model 
on our main result: community-wide treatment is highly 
cost eﬀ ective compared with school-aged children alone. 
This analysis showed study ﬁ ndings were robust with a 
mean ICER of $219 (95% CI 63–524) per DALY averted 
(appendix).
Discussion
Our modelling study has shown that integrated 
community-wide MDA targeting two major helminthiases 
is a highly cost-eﬀ ective strategy. Great progress has been 
made in decreasing the burden of helminthiases with use 
of MDA programmes, but even communities with 
repeated treatment of school-aged children have been 
unable to achieve elimination of schistosomiasis and soil-
transmitted helminthiasis.5,10,12,49 Recent models in the past 
two years have reported the potential beneﬁ ts for expansion 
of drug coverage to the entire community.5,12,13 The results 
of our study support these ﬁ ndings and suggest that 
expanded, community-wide treatment alongside high 
coverage (>75%) and sustained administration (>5 years) 
could be crucial in suﬃ  ciently decreasing the community 
worm load to prevent high reinfection rates and make 
elimination a possibility in many communities. 
Importantly, we noted that community-wide treatment 
would be highly cost eﬀ ective even if elimination could not 
be achieved, due to substantial disability averted in 
preschool-aged children, school-aged children, and adults. 
As a result, MDA will avert much disability and be highly 
cost eﬀ ective even when prevalence is not substantially 
reduced. These ﬁ ndings held true across all four 
communities in Côte d’Ivoire with diﬀ ering prevalence of 
Schistosoma and soil-transmitted helminth infections. 
Crucially, treatment of both sets of helminths was highly 
cost eﬀ ective even in communities with a low prevalence 
of one of these helminth types, because most costs were 
spent on treatment delivery and not on the drugs 
themselves. We also determined that integrated treatment 
every 6 months could be highly cost eﬀ ective. These 
ﬁ ndings lend support to the movement towards integrated 
treatment programmes for schistosomiasis and soil-
transmitted helminthiasis, and underscore the need to 
develop guidelines that address the importance of 
expanding treatment to include more than only school-
aged children and are based on the local burden of many 
helminth infections rather than each individually.
If the latest WHO guidelines6 had been followed (which 
are speciﬁ c to either schistosomiasis or soil-transmitted 
helminthiasis), individuals in only one of the four 
Figure 4: One-way sensitivity analysis of key model parameters
This analysis tested the eﬀ ect of varying key model parameters on the incremental cost-eﬀ ectiveness ratio 
(ICER) of expanding mass drug administration to entire communities compared with only treatment of 
school-aged children. The horizontal bar represents the range of ICER values for the speciﬁ ed range of the tested 
parameter. All strategies left of the dashed vertical line at US$1521 per disability-adjusted life-year (DALY) 
averted (2013 gross domestic product per capita in Côte d’Ivoire) are regarded as highly cost eﬀ ective. *Relative 
environmental contribution refers to the relative rate of excretion of eggs into the environment among 
preschool-aged children and school-aged children when compared with adults. 
Community-wide delivery cost multiplier 
(3 × per year; 1–10 × per year) 
School-based delivery cost 
(US$0·50; $0·05–1·50)
Schistosomiasis disability weight 
(0·02; 0·05–0·005)
Frequency of treatment 
(1 × per year; 1 × per 4 years–4 × per year) 
Coverage 
(75%; 100–5%)
Relative environmental contribution* 
(2 × contribution; 1–3 × contribution)
0 200 400 600 800 1000 1200 1400 1600
ICER (US$ per DALY averted)
School-aged children* Community-wide
Total costs in 
2014 (US$)
Total disability 
(DALYs)
ICER (US$ 
per DALY)
Total costs in 
2014 (US$)
Total disability 
(DALYs)
ICER (US$ 
per DALY)
No treatment 0 3252·1 NA 0 3252·1 NA
48 months 9377 3095·5 60 75 527 2652·6 126
36 months 11 712 3071·2 96 94 326 2522·2 144
24 months 18 217 3035·4 182 146 718 2250·5 Dominated†
12 months 34 122 2964·1 223 274 817 1521·6 180
6 months 68 243 2865·7 347 549 634 700·9 335
4 months 102 365 2809·7 609 824 451 366·0 821
3 months 136 486 2769·4 845 1 099 269 266·4 2758
DALY=disability-adjusted life-year. ICER=incremental cost-eﬀ ectiveness ratio. NA=not applicable. *Aged 5–14 years. 
†Dominated strategy deﬁ ned as intervention with higher ICER than more eﬀ ective strategy. 
Table 4: Costs, disability, and incremental cost-eﬀ ectiveness of varying frequency of mass drug 
administration
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communities in our study would have received integrated 
annual MDA. Individuals in the other communities 
would have received either albendazole for soil-
transmitted helminthiasis or praziquantel for 
schistosomiasis at diﬀ erent frequencies, and often would 
have omitted one of the anthelmintic drugs completely. 
However, because the costs of drugs themselves are low, 
the infrastructure to deliver MDA—particularly at the 
community level—accounts for the bulk of total costs. 
Addition of a second drug to MDA programmes therefore 
beneﬁ ts from reduced incremental costs, making their 
use cost eﬀ ective at lower prevalence values than those 
recommended in non-integrated programmes.
The cost-eﬀ ectiveness of integrated community-wide 
treatment was robust to local epidemiology and 
assumptions on cost of treatment, coverage, frequency of 
treatment, disability measurement, and prevalence of 
infection. Although the quantitative result (ICER) will vary 
in other settings as a function of local costs and disease 
burden, we believe our sensitivity analyses suggest that 
our main ﬁ nding—that integrated community-wide MDA 
is highly cost eﬀ ective—will be applicable in many low-
resource settings where schistosomiasis and soil-
transmitted helminthiasis coexist. The price of 
community-based delivery was calculated by applying a 
three-times multiplier to the school-based delivery cost, to 
account for the increased cost to administer treatment 
throughout a community. Conservatively high estimates 
for school-based delivery costs ($0·50) could make the 
absolute incremental cost between school-based and 
community-based delivery larger than the three-times 
multiplier might suggest. Community-wide treatment 
remained highly cost eﬀ ective across a large range of the 
community-wide multipliers (1–10 times) and base 
delivery costs ($0·05–1·50). The 75% coverage used in the 
main analysis, which is representative of WHO’s goal, 
provided a similar result when compared with present 
global coverage (15–30%), as shown in the sensitivity 
analysis.
The latest WHO guidelines suggest treatment of high-
risk adults in endemic regions and consideration of 
community-wide treatment for schistosomiasis in highly 
endemic communities (>50% prevalence), but this is not 
usually done in practice.50 MDA in school-aged children 
(ICER $118 per DALY averted) and community-wide 
treatment (ICER $167 per DALY averted) were both 
highly cost eﬀ ective with similar ICERs, particularly at 
coverage that exceeded 75%. Treatment of school-aged 
children and preschool-aged children or adults alone 
were dominated strategies, meaning that community-
wide treatment averted more disability at a lower 
incremental cost-eﬀ ectiveness. Following an existing 
treatment framework that focuses on treatment of 
school-aged children and school-based delivery, one 
eﬃ  cient strategy would be ﬁ rst scaling up to adequate 
coverage of school-based treatment followed by 
implementation of community-wide treatment.
Even though the speciﬁ c prevalence threshold that is 
cost eﬀ ective for inclusion of each age group was not 
examined explicitly, both school-aged children only and 
community-wide treatment were deemed highly cost 
eﬀ ective in all communities ranging from low to highly 
endemic settings. This result suggests the possibility of 
lowering prevalence thresholds used in treatment 
guidelines and the need for cost-eﬀ ectiveness work to 
inform the speciﬁ c thresholds. In line with previous 
studies, the use of mean burden (usually estimated by 
mean eggs per g of faeces) rather than prevalence of 
infection should also be thought about in creation of 
these thresholds based on the distribution of disease.13
The results of this study should be interpreted within 
the context of the limitations of model parameters and a 
number of simplifying assumptions. We modelled 
treatment as an instantaneous reduction in mean burden 
and increase in haemoglobin; annual treatment was 
applied simultaneously throughout all communities; 
perfect mixing was assumed in the subpopulation mean 
burden; coverage assumed random rather than repeated 
treatment of individuals within the population; 
heterogeneity was assumed to be constant throughout the 
population despite treatment pressure that might 
concentrate disease burden in a smaller number of hosts; 
and contributions of animal reservoirs, migration, and so-
called superspreaders (highly infectious individuals who 
transmit their infection to several other people) were not 
included and could represent important barriers to 
helminth elimination. We modelled a 15-year period, and 
assumed constant treatment coverage throughout this 
period; in reality, treatment acceptance could change over 
time. Treatment decisions were made on the basis of 
initial prevalence and were not re-evaluated during the 
simulation. However, the results show that WHO-
recommended treatment (focused on school-aged children 
only) had little eﬀ ect on prevalence (ﬁ gure 2B) and would 
be less likely to reduce prevalence substantially enough to 
change the recommended treatment strategy from WHO.
Treatment costs were not separated into the ﬁ xed 
component of setting up a programme, and a variable 
component of increasing treatment frequency or 
coverage. Helminth disease distribution was modelled 
with a negative binomial distribution after analysis with 
primary data and previous models. We did not model 
disability because of toxic eﬀ ects of therapy, as single 
dose administration is associated with a very low risk of 
substantial toxic eﬀ ects in comparison with the extent of 
disability due to disease.51 Of the most uncertain 
parameters is the relative contribution of eggs to the 
environment from each age group; we assumed that 
preschool-aged children and school-aged children 
contributed twice as much in the base case as did adults, 
and the results were ultimately minimally aﬀ ected across 
a broad range of assumptions for this parameter.
The disability weight given to schistosomiasis and soil-
transmitted helminthiasis has been much debated, and 
Articles
www.lancet.com/lancetgh   Vol 3   October 2015 e637
varies greatly depending on the published source used (ie, 
WHO [Global Burden of Disease 2004],52 and King and 
colleagues’ meta-analysis53). The disability weight for 
schistosomiasis varies from 0·005 to 0·15 on a scale from 
0 (perfect health) to 1 (death).21 We ultimately chose a 
binary disability weight of 0·02, which represents the 
lowest value of a meta-analysis that examined this 
disability weight, and assessed the eﬀ ect of this disability 
weight in sensitivity analyses.21 The disability structure for 
soil-transmitted helminthiasis was updated in 2014, and 
we used these weights.1 In view of recent controversy 
about treatment of soil-transmitted helminth infections in 
the past months,54,55 of note is that updated weights for 
these helminths did not assign any disability for light 
infections, and did not include any cognitive or educational 
beneﬁ t from treatment. By contrast, individuals with 
schistosomiasis received the same disability weight 
irrespective of infection intensity. Generally, disability 
weights for these diseases might not truly account for 
long-term cognitive impairment, which would increase 
treatment cost-eﬀ ectiveness and could favour treatment of 
preschool-aged children and school-aged children rather 
than adults. Although many studies have reported greater 
prevalence of helminths in school-aged children than in 
adults, growing scientiﬁ c literature supports our ﬁ nding 
that adults can often have equivalent or greater disease 
burden than children, especially for hookworm infections 
and schistosomiasis.56,57 To the best of our knowledge, the 
empirical data used in our study came from communities 
that had not received MDA, but there is still a potential 
undocumented exposure to anthelmintics.
We did not assess treatment of malaria, ﬁ larial 
infections, strongyloidiasis, or other helminth infections 
that are often co-endemic in many communities and can 
be treated concomitantly. Additionally, thought should be 
given to the role of diﬀ erent helminthiasis control 
methods—these include water, sanitation, and hygiene, 
community education, vaccine development, and other 
measures58,59—which are likely to be important in future 
elimination eﬀ orts but were not included in this model. 
Importantly, not every cost-eﬀ ective programme will be 
aﬀ ordable in all settings and might be subjected to 
changing funding priorities; however, our ﬁ ndings 
suggest that expanded community-wide MDA would be 
cost eﬀ ective while being undertaken, even if the 
programme was not subsequently maintained. Thus, the 
goal of this study is to assist in prioritising among the 
many needed health interventions in low-income settings.
With renewed enthusiasm for control and elimination 
eﬀ orts targeting helminth infections, questions remain 
about how to eﬀ ectively deploy resources. Present WHO 
guidelines, which are based on the individual prevalence 
of helminth infections and focus on school-aged children 
alone, are inadequate for informing treatment 
programmes. Revised guidance is urgently needed to 
inform the scale-up of treatment programmes world-
wide to avert the substantial disability created from 
soil-transmitted helminthiasis, schistosomiasis, and 
other neglected tropical diseases.
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